-
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-06 Su Wang, Mark Harrington, Camilla S Graham, Louise O Downs, Nancy Kagwanja, Anthony O Etyang, Collins Iwuji, Thumbi Ndung'u, Benjamin C Cowie, Kenneth Kabagambe, Philippa C Matthews
No Abstract
-
Shining a New Light on Gastrointestinal Endoscopy: Evaluating the Effect of Green Light Versus Dim Light on Performance in the Endoscopy Suite Gastroenterology (IF 25.7) Pub Date : 2025-02-06 Trent Walradt, Daniel Szvarca, Christopher C. Thompson
No Abstract
-
Demystifying the K Award Gastroenterology (IF 25.7) Pub Date : 2025-02-06 Michelle Kang Kim, Benjamin Chen, Melissa Martynenko, Florian Rieder, Raneem Khedraki, Anthony Lembo, Jenny J. Lin
No Abstract
-
Bridging the gap between science and survival Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-07 Ahsen Ustaoglu
A scientist’s personal journey through breast cancer underscores the urgency for greater empathy in research and healthcare, a patient-centred approach to data dissemination, and more comprehensive, streamlined support for early-career researchers navigating health crises.
-
Alterations in mucosa branched N-glycans lead to dysbiosis and downregulation of ILC3: a key driver of intestinal inflammation. Gut Microbes (IF 12.2) Pub Date : 2025-02-07 Cláudia S Rodrigues,Joana Gaifem,Márcia S Pereira,Maria Francisca Alves,Mariana Silva,Nuno Padrão,Bruno Cavadas,Catarina Moreira-Barbosa,Inês Alves,Ricardo Marcos-Pinto,Joana Torres,Aonghus Lavelle,Jean-Frederic Colombel,Harry Sokol,Salomé S Pinho
The perturbation of the symbiotic relationship between microbes and intestinal immune system contributes to gut inflammation and Inflammatory Bowel Disease (IBD) development. The host mucosa glycans (glycocalyx) creates a major biological interface between gut microorganisms and host immunity that remains ill-defined. Glycans are essential players in IBD immunopathogenesis, even years before disease
-
Early life gut microbiome and its impact on childhood health and chronic conditions. Gut Microbes (IF 12.2) Pub Date : 2025-02-07 Harold Nunez,Pamela A Nieto,Ruben A Mars,Maryam Ghavami,Cheryl Sew Hoy,Kimberley Sukhum
The development of the gut microbiome is crucial to human health, particularly during the first three years of life. Given its role in immune development, disturbances in the establishment process of the gut microbiome may have long term consequences. This review summarizes evidence for these claims, highlighting compositional changes of the gut microbiome during this critical period of life as well
-
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-06 Maria José Temido, Sailish Honap, Vipul Jairath, Severine Vermeire, Silvio Danese, Francisco Portela, Laurent Peyrin-Biroulet
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the increasingly ambitious treatment targets have led to an increased use of advanced therapies and better outcomes. Nevertheless, many patients remain suboptimally treated and are at risk of disease progression, hospital admission, and surgery
-
Geographic Disparities in Access to Gastroenterologists in the United States Gastroenterology (IF 25.7) Pub Date : 2025-02-06 Xiaohan Ying, Leah Yao, Walter S. Mathis, Stephen E. Congly, Arun B. Jesudian
No Abstract
-
Histology of subepithelial lesions (SELs) in the gastrointestinal tract-resected endoscopic: a database study of 4901 patients. Gut (IF 23.0) Pub Date : 2025-02-06 Zhipeng Qi,Enpan Xu,Shuchang Xu,Leiming Xu,XiaoBo Li,Liang Zhong,Dongli He,Pinghong Zhou,Zhendong Jin,Yunshi Zhong,
-
Post sleeve gastrectomy-enriched gut commensal Clostridia promotes secondary bile acid increase and weight loss. Gut Microbes (IF 12.2) Pub Date : 2025-02-06 Shaoqian Zhao,Huibin Lin,Wen Li,Xiaoqiang Xu,Qihan Wu,Zhifeng Wang,Juan Shi,Yufei Chen,Lingxia Ye,Liuqing Xi,Lijia Chen,Mingyang Yuan,Junlei Su,Aibo Gao,Jiabin Jin,Xiayang Ying,Xiaolin Wang,Yaorui Ye,Yingkai Sun,Yifei Zhang,Xiaxing Deng,Baiyong Shen,Weiqiong Gu,Guang Ning,Weiqing Wang,Jie Hong,Jiqiu Wang,Ruixin Liu
The gut microbiome is altered after bariatric surgery and is associated with weight loss. However, the commensal bacteria involved and the underlying mechanism remain to be determined. We performed shotgun metagenomic sequencing in obese subjects before and longitudinally after sleeve gastrectomy (SG), and found a significant enrichment in microbial species in Clostridia and bile acid metabolizing
-
Mirikizumab for Crohn’s Disease: Small Step Forward or Giant Leap Ahead? Gastroenterology (IF 25.7) Pub Date : 2025-02-04 Christopher Ma
No Abstract
-
Overlap of Genomic and Transcriptomic Genes Identified in Familial Eosinophilic Esophagitis Gastroenterology (IF 25.7) Pub Date : 2025-02-04 Kristina Allen-Brady, Frederic Clayton, Mark W. Hazel, Jeff Stevens, Ashley L. Pyne, Maria A. Pletneva, Melissa Cessna, Chris Stubben, Jacob Robson, John Fang, Kathryn A. Peterson
-
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024 Gastroenterology (IF 25.7) Pub Date : 2025-02-04 Anne F. Peery, Caitlin C. Murphy, Chelsea Anderson, Elizabeth T. Jensen, Sasha Deutsch-Link, Matthew D. Egberg, Jennifer L. Lund, Disha Subramaniam, Evan S. Dellon, Ami D. Sperber, Olafur S. Palsson, Virginia Pate, Todd H. Baron, Andrew M. Moon, Nicholas J. Shaheen, Robert S. Sandler
BackgroundA contemporary report describing the burden and expenditures of gastrointestinal (GI) diseases can be helpful for policy makers, administrators, and researchers. Using the most recent data, we estimated the burden and costs associated with GI diseases in the United States. MethodsWe generated estimates using data from the Rome Foundation Global Epidemiology Study 2017–2018 (symptoms), National
-
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-05 Timothy M. Block, Ju-Tao Guo, Fabien Zoulim, Charles M. Rice, Chloe L. Thio, William M. Schneider, Harvey J. Alter, Ira M. Jacobson, Robert G. Gish, Peter D. Block, Mark Sulkowski, Jordan J. Feld, Chari A. Cohen
-
Archaea methanogens are associated with cognitive performance through the shaping of gut microbiota, butyrate and histidine metabolism. Gut Microbes (IF 12.2) Pub Date : 2025-02-05 Andrea Fumagalli,Anna Castells-Nobau,Dakshat Trivedi,Josep Garre-Olmo,Josep Puig,Rafel Ramos,Lluís Ramió-Torrentà,Vicente Pérez-Brocal,Andrés Moya,Jonathan Swann,Elena Martin-Garcia,Rafael Maldonado,José Manuel Fernández-Real,Jordi Mayneris-Perxachs
The relationship between bacteria, cognitive function and obesity is well established, yet the role of archaeal species remains underexplored. We used shotgun metagenomics and neuropsychological tests to identify microbial species associated with cognition in a discovery cohort (IRONMET, n = 125). Interestingly, methanogen archaeas exhibited the strongest positive associations with cognition, particularly
-
Is It Time to Scale Down the Bristol? Am. J. Gastroenterol. (IF 8.0) Pub Date : 2025-02-05 Peter L Lu
-
Lyon Score: Key Deficiencies and Discrepancies. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2025-02-05 Arianna Vittori,Andrés R Latorre-Rodríguez,Sumeet K Mittal
-
A Global Perspective on Metabolically Driven Primary Liver Cancer: Opportunities and Challenges. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2025-02-05 Joseph C Ahn
-
Effects of Cholestasis on Primary Sclerosing Cholangitis in Patients Following Liver Transplantation: Insights From Mixed Censoring Outcomes. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2025-02-05 Lingyu Xu,Xuefei Shen,Yan Xu
-
Predictors for chronic opioid use in patients with inflammatory bowel disease - a population based cohort study. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2025-02-05 Bente Mertz Nørgård,Caroline Thingholm Thorarinsson,Jan Nielsen,Rahul S Dalal,Mette Louise Andersen,Ken Lund,Sonia Friedman,Torben Knudsen,Jens Kjeldsen
BACKGROUND A significant proportion of patients with Crohn's disease (CD) and ulcerative colitis (UC) become opioid users, but data pertaining to predictors of chronic opioid use remain sparse. OBJECTIVE We examined predictors for chronic opioid use in CD/UC. DESIGN A nationwide cohort study based on Danish registries, comprising incident patients with CD/UC (≥ 18 years) from January 1, 1996-December
-
Large Single Center Comparison Of Novel and Reusable Duodenoscopes Show Similar Contamination Rates That Do Not Correlate With Clinical Infection. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2025-02-05 Sriya Muralidharan,Divya Chalikonda,Grace Kim,Miles Breese,Marilu Andrade,Eric Montminy,Dennis Chen,Uzma Siddiqui
INTRODUCTION There are limited data comparing the contamination rates of reusable and novel duodenoscopes with disposable components. The clinical implications of novel duodenoscope bacterial contamination are also unknown. This study aimed to evaluate the rate of pathogenic bacterial contamination of novel and reusable duodenoscopes and assess the clinical implications for patients exposed to contaminated
-
Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Ariel Lee, Kali Zhou
Chronic hepatitis B virus (HBV) infection remains a leading cause of liver disease worldwide, with a risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Currently, nucleoside analogues entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are recommended equally by guidelines as first-line antiviral therapy for chronic HBV and are the most common therapies in high-income countries
-
Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Brian C. Weiner
Careful planning helps to get reliable results and avoids mistakes. The publication by Dulai et al. [1] shows the work involved in a major multicentre project to demonstrate the feasibility for a new treatment in an area sorely lacking in recent innovation. Hyperbaric oxygen (HBO) is purported to be helpful in management of severe inflammatory bowel disease (IBD) due to its known effect of increasing
-
Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV‐Infected HCC Patients Undergoing Immunotherapy Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Jialing Wang, Wenjun Meng
We have perused with intrigue the original article by Hung et al., which appraises the efficacy of nucleos/tide analogue (NUC) prophylaxis for downgrading the HBV reactivation (HBVr) in patients with hepatocellular carcinoma (HCC) receiving immunotherapies [1]. Besides, the study emphasised that abnormal baseline alanine aminotransferase (ALT) levels can be identified as a significant risk factor for
-
Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Lingna Ye, Yushu Cao, Yujuan Fu, Chuwen Tian, Qian Cao
-
Letter: Hepatotoxicity in Malignancies Under ICIs Treatment Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Yue Zou, Zhengyu Zhang, Jianjun He
We had the pleasure of reading the research article by Hung et al. [1] We sincerely appreciate their meticulous work and significant contributions, and we hope to offer some constructive suggestions for future research. Firstly, the article provides a comprehensive account of the patients' baseline data and outlines the baseline demographic characteristics of the study population, which is commendable
-
Editorial on ‘Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’ Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Ming Chao Tsai, Tsung Hui Hu
Cessation of nucleos(t)ide analogue (NA) can lead to the restoration of the immune system and ultimately result in higher rates of functional cure in a selected group of patients with chronic hepatitis B (CHB). However, off-treatment viral relapse is common and may lead to hepatic flares, hepatic decompensation or even death [1-3]. Consequently, identifying biomarkers and high-risk patient characteristics
-
Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Xiaojuan Liu, Xueru Huang, Mingsi Zhang, Tao Jiang, Guangji Zhang
We were intrigued by the study conducted by Amangurbanova et al. [1], which examined the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM) and hyperferritinaemia. The authors proposed elevated serum ferritin as a potential biomarker for MASLD and significant fibrosis, while also elucidating the risk characteristics associated
-
Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Changhu Sun, Zeping Chen, Lincheng Duan
We have carefully reviewed the recently published article, ‘Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk’ [1]. This study highlights the critical role of hepatic steatosis (HS) as a cardiovascular risk enhancer, particularly in individuals traditionally considered to have low-to-intermediate atherosclerotic
-
Letter: Enhancing the Analysis and Clinical Applicability of Ferritin as a Biomarker for MASLD in Type 2 Diabetes Patient Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Pengfei Xi, Hai Li, Shengxian Li
We were very interested to read the article by Amangurbanova et al. published in the Journal [1]. This study provides valuable insights into the association between hyperferritinaemia and metabolic dysfunction-associated steatotic liver disease (MASLD), as well as hepatic fibrosis, in patients with type 2 diabetes mellitus (T2DM). In addition to the limitations the authors mentioned, we believe that
-
Applying the estimand framework to inflammatory bowel disease clinical trials Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-03 Nurulamin M Noor, Maria Manuela Estevinho, Virginia Solitano, Yuhong Yuan, Brennan C Kahan, Vipul Jairath
No Abstract
-
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-03 Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, Chi-Yi Chen, Won-Mook Choi, Wonseok Kang, Gi-Ae Kim, Hyung Joon Kim, Yun Bin Lee, Jeong-Hoon Lee, Neung Hwa Park, So Young Kwon, Soo Young Park, Ji Hoon Kim, Gwang Hyeon Choi, Eun Sun Jang, Chien-Hung Chen, Yao-Chun Hsu, Ming-Jong Bair, Pin-Nan Cheng, Seungbong Han
BackgroundCurrent guidelines for chronic hepatitis B recommend antiviral therapy for individuals with non-cirrhotic chronic hepatitis B only if they have significant liver fibrosis or elevated alanine aminotransferase (ALT) concentrations. We aimed to assess the efficacy of early antiviral treatment in preventing serious liver-related adverse events in individuals with non-cirrhotic chronic hepatitis
-
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-03 Asgeir Johannessen
No Abstract
-
A Standardized Approach to Performing and Interpreting FLIP Panometry for Esophageal Motility Disorders: The Dallas Consensus Gastroenterology (IF 25.7) Pub Date : 2025-02-04 Dustin A. Carlson, John E. Pandolfino, Rena Yadlapati, Marcelo F. Vela, Stuart J. Spechler, Felice H. Schnoll-Sussman, Kristle Lynch, Adriana Lazarescu, Abraham Khan, Philip Katz, Anand S. Jain, C. Prakash Gyawali, Milli Gupta, Jose M. Garza, Ronnie Fass, John O. Clarke, Reena V. Chokshi, Joan Chen, Karthik Ravi, Walter W. Chan, Vani J.A. Konda
Background and aimsFunctional lumen imaging probe (FLIP) Panometry provides assessment of the esophagogastric junction (EGJ) opening and esophageal body contractile activity during an endoscopic procedure and is increasing being incorporated in comprehensive esophageal motility assessments. We aimed to provide a standardized approach and vocabulary to the procedure and interpretation and update the
-
Is Fecal Immunochemical Testing the Right FIT for Patients With Symptoms? Gastroenterology (IF 25.7) Pub Date : 2025-02-04 Audrey H. Calderwood, Theodore R. Levin
Section snippets Uncited FigureFigure 1
-
Prevalence of Chronic Liver Diseases and Associated Risk Factors in Sexual Minority People in The United States Gastroenterology (IF 25.7) Pub Date : 2025-02-04 Tzu-Hao Lee, George Cholankeril, Dongehee Kim, Ruben Hernaez, Kira L. Newman
No Abstract
-
Liver Health: An Emerging Concept Gastroenterology (IF 25.7) Pub Date : 2025-02-03 Pere Ginès, Indra Neil Guha, Núria Fabrellas, Alina M. Allen, Paolo Angeli, Miquel Serra-Burriel
No Abstract
-
Is precision microbiome medicine just around the corner? Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-04 Silvia Turroni
A study in Nature Medicine developed a new clinical test based on a gut metagenome-derived multispecies biomarker panel for the diagnosis of inflammatory bowel disease, which outperformed faecal calprotectin. Shortly after, a study in Cell identified a health-relevant network-based core microbiome that could substantially advance precision microbiome medicine.
-
MASLD as a non-communicable disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-04 Silvia Sookoian, Carlos J. Pirola, Arun J. Sanyal
Non-communicable diseases represent the primary cause of mortality and morbidity globally, accounting for 74% of all deaths and more than three-quarters of years lived with disability. Here, we argue that metabolic dysfunction-associated steatotic liver disease should be considered a non-communicable disease.
-
Dysbiotic oral microbiota-derived kynurenine, induced by chronic restraint stress, promotes head and neck squamous cell carcinoma by enhancing CD8+ T cell exhaustion. Gut (IF 23.0) Pub Date : 2025-02-04 Fangzhi Lou,Li Yan,Shihong Luo,Yunmei Dong,Jingyi Xu,Ning Kang,Haiyang Wang,Yiyun Liu,Juncai Pu,Bing Yang,Richard D Cannon,Peng Xie,Ping Ji,Xin Jin
BACKGROUND Chronic restraint stress (CRS) is a tumour-promoting factor. However, the underlying mechanism is unknown. OBJECTIVE We aimed to investigate whether CRS promotes head and neck squamous cell carcinoma (HNSCC) by altering the oral microbiota and related metabolites and whether kynurenine (Kyn) promotes HNSCC by modulating CD8+ T cells. DESIGN 4-nitroquinoline-1-oxide (4NQO)-treated mice were
-
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications. Gut (IF 23.0) Pub Date : 2025-02-04 Victoria Gudiño,Raquel Bartolomé-Casado,Azucena Salas
Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn's disease (CD), are chronic conditions characterised by inflammation of the intestinal tract. Alterations in virtually all intestinal cell types, including immune, epithelial and stromal cells, have been described in these diseases. The study of IBD has historically relied on bulk transcriptomics, but this method averages
-
Carbon footprinting and environmental impact of gastrointestinal endoscopy procedures at a tertiary care institution: a prospective multi-dimensional assessment. Gut (IF 23.0) Pub Date : 2025-02-04 Hardik Rughwani,Rakesh Kalapala,Anudeep Katrevula,Nitin Jagtap,Madhav Desai,Sara Teles de Campos,Mohan Ramchandani,Sundeep Lakhtakia,Rupjyoti Talukdar,Santosh Darisetty,Sana Fatima Memon,Guduru Venkat Rao,Marco Bruno,Prateek Sharma,D Nageshwar Reddy
BACKGROUND Given the imperative to combat climate change, reducing the healthcare sector's implications on the environment is crucial. OBJECTIVE This study aims to offer a comprehensive assessment of the environmental impact of gastrointestinal endoscopy (GIE) procedures, specifically focusing on greenhouse gas (GHG) emissions and waste generation. DESIGN A prospective study was conducted at the Asian
-
PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg). Am. J. Gastroenterol. (IF 8.0) Pub Date : 2025-02-04 Diego Casas Deza,Javier Alcedo,Miguel Lafuente,F Javier López,Ángeles Perez-Aisa,Matteo Pavoni,Bojan Tepes,Laimas Jonaitis,Manuel Castro-Fernandez,Manuel Pabón-Carrasco,Alma Keco-Huerga,Irina Voynovan,Luis Bujanda,Alfredo J Lucendo,Natasa Brglez Jurecic,Maja Denkovski,Ludmila Vologzanina,Luis Rodrigo,Samuel J Martínez-Domínguez,Galyna Fadieienko,Jose M Huguet,Rustam Abdulkhakov,Sayar R Abdulkhakov
AIM To evaluate the prescriptions patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe. DESIGN International, prospective, non-interventional registry of the clinical practice of the European gastroenterologists. Data were collected and quality reviewed until March 2021 at AEG-REDCap. The effectiveness was evaluated by modified intention-to-treat
-
A Microbiome-directed therapy for malnutrition that performs better than standard nutritional interventions. Gastroenterology (IF 25.7) Pub Date : 2025-02-03 Alain J. Benitez, Kara Gross Margolis
No Abstract
-
Gut Microbiome Signature in Predisease Phase of Inflammatory Bowel Disease: Prediction to Pathogenesis to Prevention Gastroenterology (IF 25.7) Pub Date : 2025-02-03 Williams Turpin, Sun-Ho Lee, Ken Croitoru
Advances in understanding the pathogenesis of inflammatory bowel disease (IBD) point toward a key role of the gut microbiome. We review the data describing the changes in the gut microbiome from IBD case-control studies and compare these findings with emerging data from studies of the preclinical phase of IBD. What is apparent is that assessing changes in the composition and function of the gut microbiome
-
Biofilm-associated proteins: from the gut biofilms to neurodegeneration. Gut Microbes (IF 12.2) Pub Date : 2025-02-03 Jaione Valle
Human microbiota form a biofilm with substantial consequences for health and disease. Numerous studies have indicated that microbial communities produce functional amyloids as part of their biofilm extracellular scaffolds. The overlooked interplay between bacterial amyloids and the host may have detrimental consequences for the host, including neurodegeneration. This work gives an overview of the biofilm-associated
-
Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-03 Michael Camilleri, Alexander C. Ford
-
AhR Activation Transcriptionally Induces Anti-Microbial Peptide Alpha-Defensin 1 Leading to Reversal of Gut Microbiota Dysbiosis and Colitis. Gut Microbes (IF 12.2) Pub Date : 2025-02-02 Manikandan Palrasu,Khadija Kakar,Amarnath Marudamuthu,Hamida Hamida,Shruthi Thada,Yin Zhong,Shanieka Staley,Philip Brandon Busbee,Jie Li,Monica Garcia-Buitrago,Mitzi Nagarkatti,Prakash Nagarkatti
Alpha-defensin 1 is a small antimicrobial peptide that acts as the first line of defense against pathogens. It is induced following microbial cues and inflammatory signals in neutrophils and Paneth cells in the small intestine, which suggests that it plays a role in microbial homeostasis in the gut. The gut microbial products also serve as ligands for the aryl hydrocarbon receptor (AhR), an environmental
-
First-line dual immunotherapy to checkmate metastasic colorectal cancer with high microsatellite instability Gastroenterology (IF 25.7) Pub Date : 2025-02-01 Maria D. Giraldez
No Abstract
-
Comments on “Recompensation of Chronic Hepatitis C–Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program” Gastroenterology (IF 25.7) Pub Date : 2025-02-01 Niteen Kumar, Abhideep Chaudhary
No Abstract
-
Names matter: a call to neurogastroenterologists to examine how we can improve the nomenclature we use to describe the disorders our patients experience Gastroenterology (IF 25.7) Pub Date : 2025-02-01 Pankaj J. Pasricha, Nicholas J. Talley, Linda Nguyen, Thomas Abell, John Furness, Mark Pimentel
No Abstract
-
A new tool to study the DREADDed peripheral nervous system Gastroenterology (IF 25.7) Pub Date : 2025-02-01 Amber L. Alhadeff, Brian J. DeBosch
No Abstract
-
“A rose by any other name”? — Beyond Diagnostic Nomenclature in Neurogastroenterology Gastroenterology (IF 25.7) Pub Date : 2025-02-01 Daniel Keszthelyi, Laurie Keefer
No Abstract
-
Acute Liver Failure and a Rash Gastroenterology (IF 25.7) Pub Date : 2025-01-31 Emily R. Gordon, Madison E. Jones, Brandon L. Adler
No Abstract
-
A novel, IBS-specific IgG ELISA-based elimination diet in irritable bowel syndrome: A randomized, sham-controlled trial Gastroenterology (IF 25.7) Pub Date : 2025-01-31 Prashant Singh, William D. Chey, Will Takakura, Brooks D. Cash, Brian E. Lacy, Eamonn M.M. Quigley, Charles W. Randall, Anthony Lembo
Background & AimsPersonalized dietary therapies for irritable bowel syndrome (IBS) are needed and an IgG-antibody-based elimination diet presents a potential solution. However, existing studies have serious methodological limitations. This study aimed to assess the efficacy of an elimination diet utilizing a novel IBS-specific IgG assay. MethodsWe conducted a randomized, double-blind, sham-controlled
-
An Unexpected Adverse Event of Radiofrequency Ablation for Intraductal Papillary Mucinous Neoplasm Gastroenterology (IF 25.7) Pub Date : 2025-01-31 Ahmed Abdelbaki, Fadi Hawa, Somashekar G. Krishna
No Abstract
-
Editorial: Autoimmune Hepatitis—Could It Be as Easy as Vitamin D? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-01 Jessica K. Dyson
Despite increasing knowledge regarding pathogenesis and risk factors in autoimmune hepatitis (AIH), there is still significant morbidity and mortality associated with both the disease and its treatments. Here, Kilani et al. [1] examine the impact of vitamin D levels on AIH outcomes, stratifying by deficiency, insufficiency and normal levels. This builds on previous work showing links between vitamin
-
Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-01 Courtney Bartel, Phillip Minar
The pharmacokinetics of IBD biologics in children differ from adults. Differences are thought to be related to physiological (e.g., differences in body surface area and a higher rate of hypoalbuminemia), developmental (immature immune processing and higher prevalence of anti-drug antibody formation) and disease-related (e.g., severity and extent of inflammation) factors [1, 2]. Therapeutic drug monitoring
-
Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-01 Chia‐Chih Kuo, Chun‐Hsien Li, Min‐Hsiang Chuang, Po‐Yu Huang, Hsing‐Tao Kuo, Chih‐Cheng Lai
-
The safety and efficacy of guselkumab for the treatment of moderate to severely active ulcerative colitis Gastroenterology (IF 25.7) Pub Date : 2025-01-31 Reena Khanna
No Abstract